Company news

KalVista Pharmaceuticals, Inc. news in 2024

KalVista Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

KalVista Appoints Jeb Ledell as Chief Operating Officer

December 15, 2024

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

December 4, 2024

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

November 25, 2024

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

November 3, 2024

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

November 3, 2024

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

October 27, 2024

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

October 17, 2024

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

October 3, 2024

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

September 29, 2024

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

September 25, 2024

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

September 9, 2024

KalVista Appoints Brian Piekos as Chief Financial Officer

September 9, 2024

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

September 5, 2024

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

September 4, 2024

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

September 2, 2024

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

August 28, 2024

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

August 14, 2024

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

July 10, 2024

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

June 26, 2024

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

June 17, 2024

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

June 5, 2024

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

June 2, 2024

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

May 30, 2024

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

May 23, 2024

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

April 30, 2024

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

April 21, 2024

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

March 17, 2024

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

March 11, 2024

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

March 7, 2024

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

March 6, 2024

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

March 5, 2024

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 26, 2024

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 25, 2024

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

February 19, 2024

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 15, 2024

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

February 14, 2024

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

February 13, 2024

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

February 12, 2024

Decks in 2024